STERIS Sets Rates On $1.5 Billion In Bonds For Pending Xodus Medical Purchase

The financing combines bonds, delayed-draw loan borrowings and existing cash, with bond repayment due in 2033 and 2036.

Share
STERIS Sets Rates On $1.5 Billion In Bonds For Pending Xodus Medical Purchase

STERIS, which sells infection-prevention products and services, priced $1.5 billion in bonds Monday to help finance its pending purchase of Xodus Medical and related entities. The company said in an 8-K filed Thursday that it plans to combine the bond proceeds with loan borrowings and cash on hand.

Two Maturities, Two Interest Rates

STERIS split the offering into equal $750 million portions: bonds due in 2033 will pay 5.650% annually, while those due in 2036 will pay 5.875%. Interest payments are scheduled for June 15 and December 15, starting June 15, 2027.

Its wholly owned financing subsidiary, STERIS Irish FinCo Unlimited Company, is issuing the debt. STERIS and its subsidiaries will guarantee repayment, with no assets pledged as collateral.

J.P. Morgan Securities, Goldman Sachs and Citigroup Global Markets led the underwriting. BofA Securities, PNC Capital Markets and Wells Fargo Securities are also joint book-running managers.

Loans And Cash Join The Bonds

STERIS agreed on October 11 to buy all equity interests in Xodus Medical and the related entities Kaforey Holdings III and Kaforey Management. The purchase remains pending.

The financing includes a $500 million delayed-draw term loan facility, which allows borrowing at a later point. The company plans to use loan borrowings alongside the bond proceeds and existing cash to pay for the acquisition.

STERIS also intends to arrange a $1.6 billion revolving credit facility to replace its existing facility. A revolver permits repeated borrowing and repayment. Both credit facilities are unsecured.

The company plans to apply the financing to transaction costs, general corporate expenses and working capital as well as the purchase price.

From Sterilizers To Contract Testing

STERIS serves healthcare providers and medical-device and pharmaceutical customers through its Healthcare, Applied Sterilization Technologies and Life Sciences businesses. Its products range from detergents and endoscopy accessories to sterilizers and surgical tables.

Services include equipment maintenance, instrument repair, contract sterilization and laboratory testing. Most revenue comes from healthcare, medical-device and pharmaceutical customers.

STERIS expects the bond offering to close around November 24, 2026, when payment and delivery are scheduled.

Sources

More on STERIS

All STERIS (STE) coverage →